History
  • No items yet
midpage
Peo in Interest of Kreidler
24CA1178
| Colo. Ct. App. | Sep 12, 2024
|
Check Treatment
Opinion Summary

Facts

  1. Former participants in a terminated employee stock ownership plan (“ESOP”) allege fiduciary duty breaches under ERISA by individuals and companies involved in 80/20, Inc. [lines="1-14"].
  2. Donald Wood, founder of 80/20, established a succession plan for employee ownership through an ESOP in 2016 [lines="20-50"].
  3. The ESOP controlled by the company's directors was to purchase shares upon Donald Wood’s death, allowing for offers to be made to the ESOP [lines="49-88"].
  4. Following Donald Wood's death, negotiations for the sale of shares occurred between the estate and third parties, with the ESOP's valuation submitted late [lines="92-104"].
  5. Plaintiffs filed their lawsuit, claiming that the defendants breached their fiduciary roles by failing to enact the ESOP’s right to purchase the shares [lines="181-187"].

Issues

  1. Did the plaintiffs have a right to purchase the shares of 80/20 under the codicil and Buy-Sell Agreement? [lines="328-380"].
  2. Did the delay in executing the purchase due to fiduciary mismanagement by Eagle cause the plaintiffs to miss an investment opportunity? [lines="440-442"].

Holdings

  1. The court found that the plaintiffs did not have a right to purchase the shares, only an entitlement to an offer, which was adequately provided [lines="420-480"].
  2. The court ruled that Eagle’s delay in facilitating the ESOP's purchase constituted a breach of fiduciary duty, recognizing the injury from the delayed action [lines="461-472"].

OPINION

24CA1178 Peo in Interest of Kreidler 09-12-2024
COLORADO COURT OF APPEALS
Court of Appeals No. 24CA1178
Pueblo County District Court No. 23MH371
Honorable Timothy O’Shea, Judge
The People of the State of Colorado,
Petitioner-Appellee,
In the Interest of Richard Dana Kreidler,
Respondent-Appellant.
ORDER AFFIRMED
Division II
Opinion by JUDGE SCHOCK
Fox and Johnson, JJ., concur
NOT PUBLISHED PURSUANT TO C.A.R. 35(e)
Announced September 12, 2024
Cynthia L. Mitchell, County Attorney, Kate H. Shafer, Special Assistant County
Attorney, Pueblo, Colorado, for Petitioner-Appellee
Tezak Law, P.C., Mary Tezak, Florence, Colorado, for Respondent-Appellant
1
¶ 1 Respondent, Richard Dana Kreidler, appeals the district
court’s order authorizing staff at the Colorado Mental Health
Hospital in Pueblo (CMHHIP), or any other designated facility, to
involuntarily administer medication to him. We affirm.
I. Background
¶ 2 Kreidler was committed to CMHHIP for competency restoration
in a criminal case. He was diagnosed with schizoaffective disorder
bipolar type and presented with symptoms that included delusions,
significant mood shifts, and response to internal stimuli.
¶ 3 Kreidler’s criminal charges were dismissed after he was found
permanently incompetent to proceed due to chronic psychosis. But
he has remained hospitalized at CMHHIP on a civil commitment,
having been assessed as gravely disabled and a danger to others.
¶ 4 Kreidler has been subject to multiple involuntary treatment
orders based on his refusal to take the antipsychotic and mood
stabilizing medication prescribed for him. The People’s most recent
petition for review of Kreidler’s refusal of treatment and involuntary
administration of medication is the subject of this appeal.
¶ 5 The district court held an evidentiary hearing on the petition.
Dr. Charles Dygert, a CMHHIP staff psychiatrist and Kreidler’s
2
attending psychiatrist, testified, as did Kreidler. At the end of the
hearing, the district court found that Dr. Dygert had testified
“credibly and persuasively,” and it concluded that the People had
proved all four elements set forth in People v. Medina, 705 P.2d 961
(Colo. 1985). The court issued an order authorizing CMHHIP staff
to administer to Kreidler the requested medications — Depakote,
Seroquel, Caplyta/Lumateperone, and Zyprexa/Olanzapine.
II. Analysis
¶ 6 Kreidler contends that the evidence presented at the hearing
was insufficient to prove the fourth Medina factor: that his need for
treatment is sufficiently compelling to override his bona fide and
legitimate interest in refusing treatment. We are not persuaded.
A. Applicable Law and Standard of Review
¶ 7 A district court may order the involuntary administration of
medication to a patient only if the People prove, by clear and
convincing evidence, each of the four factors outlined in Medina:
(1) the patient is incompetent to effectively participate in the
treatment decision;
(2) treatment by antipsychotic medication is necessary to
prevent a significant and likely long-term deterioration in
3
the patient’s mental condition or to prevent the likelihood
of the patient’s causing serious harm to himself or others
in the institution;
(3) a less intrusive treatment alternative is not available; and
(4) the patient’s need for treatment by antipsychotic
medication is sufficiently compelling to override any bona
fide and legitimate interest of the patient in refusing
treatment.
Id. at 973.
1
A psychiatrist’s testimony may suffice to meet this
burden. People v. Pflugbeil, 834 P.2d 843, 847 (Colo. App. 1992).
¶ 8 When a patient challenges the sufficiency of the evidence
supporting an involuntary medication order, we review the district
court’s legal conclusions de novo but defer to its findings of fact if
they have record support. People v. Marquardt, 2016 CO 4, ¶ 8. We
view the evidence as a whole and in the light most favorable to the
1
When the state seeks to administer antipsychotic drugs
involuntarily to a criminal defendant to render them competent to
stand trial, a reviewing court applies the test in Sell v. United
States, 539 U.S. 166, 178 (2003). But state law tests apply when
the state seeks to administer antipsychotic drugs involuntarily for a
different purpose, including a purpose “related to the individual’s
dangerousness, or . . . the individual’s own interests where refusal
to take drugs puts his health gravely at risk.” Id. at 181-82.
4
People to determine if it is sufficient to support the district court’s
order. People in Interest of R.K.L., 2016 COA 84, ¶ 13. If it is, we
may not substitute our judgment for that of the district court. See
People in Interest of A.J.L., 243 P.3d 244, 255 (Colo. 2010).
B. Fourth Medina Factor
¶ 9 The fourth Medina factor requires a court to first determine
“whether the patient’s refusal is bona fide and legitimate.” Medina,
705 P.2d at 974. If so, the court must determine “whether the
prognosis without treatment is so unfavorable that the patient’s
personal preference must yield to the legitimate interests of the
state in preserving the life and health of the patient placed in its
charge and in protecting the safety of those in the institution.” Id.
¶ 10 The district court found, with record support, that Kreidler
had failed to identify any legitimate reason for refusing the
requested medications. Dr. Dygert testified that he knew of no
bona fide or legitimate reason for Kreidler’s refusal to take the
medications and that such refusal was irrational and unreasonable
under the circumstances. He explained that the medications did
not have any negative effect on Kreidler’s overall health. And the
5
only negative side effect Kreidler identified was that the medications
“make [him] less effective, I think — getting things accomplished.”
¶ 11 Kreidler contends on appeal that he has a legitimate interest
in maintaining bodily autonomy and avoiding severe side effects.
He points to Dr. Dygert’s testimony about the potential side effects
of the medications, as well as Kreidler’s history of “significant
Parkinsonian-type symptoms” caused by previous medications.
¶ 12 But Dr. Dygert explained that his focus had been on “trying to
find a medication that’s effective, but that has a minimal amount of
those [Parkinsonian] side effects.” He testified that Kreidler was not
experiencing any of those side effects under his current medication
regimen. Indeed, the reason Dr. Dygert wanted to start Kreidler on
Caplyta is that it is “one of the least likely” medications to cause
Parkinsonian side effects while also “likely to be somewhat more
effective for [Kreidler’s] symptoms.” The district court specifically
acknowledged this point, noting that “Caplyta is least likely to
cause side effects for this patient.” The only other side effect Dr.
Dygert testified that Kreidler had experienced was “some sedation,”
but the Caplyta was expected to help with that issue as well. This
6
record amply supports the district court’s finding that Kreidler did
not have a bona fide and legitimate interest in refusing treatment.
¶ 13 Moreover, even if Kreidler did have a bona fide and legitimate
interest in refusing treatment, the record supports the district
court’s finding that Kreidler’s need for medication is sufficiently
compelling to override that interest. Dr. Dygert testified that the
failure to medicate Kreidler would be more harmful than the risk
posed by the medications. In particular, he opined that without the
medications, Kreidler “would be greatly disabled, not able to
manage his . . . basic needs, as well as a potential danger to
others.” The district court credited Dr. Dygert’s testimony, finding
it both credible and persuasive, and we must defer to those
findings. See People in Interest of Ramsey, 2023 COA 95, ¶ 59.
III. Disposition
¶ 14 The order is affirmed.
JUDGE FOX and JUDGE JOHNSON concur.

Case Details

Case Name: Peo in Interest of Kreidler
Court Name: Colorado Court of Appeals
Date Published: Sep 12, 2024
Docket Number: 24CA1178
Court Abbreviation: Colo. Ct. App.
Read the detailed case summary
AI-generated responses must be verified and are not legal advice.
Your Notebook is empty. To add cases, bookmark them from your search, or select Add Cases to extract citations from a PDF or a block of text.